Tuesday's IBD 50 Stocks To Watch pick is biotech stock ADMA Biologics (ADMA), which is back above a recent buy point. ADMA stock is also the No. 1-ranked stock on the IBD 50 list, which makes it one of the best ideas to watch right now.
The company develops specialty plasma-derived human immune globulin, essentially blood protein products. The treatments are used to prevent and treat infectious diseases in patients with immunodeficiencies.
↑ XThe biopharmaceutical company has three products approved by the Food and Drug Administration. It is developing a pneumonia biologic and has an ongoing pediatric clinical study for Asceniv.
Asceniv is a cocktail created from super donors whose plasma contains a high level of antibodies capable of handling respiratory syncytial virus, or RSV. RSV is a seasonal virus that can be serious or even deadly in people with insufficient immune systems, particularly newborns and older adults. Demand for Asceniv has skyrocketed, thanks to its strong effectiveness.
On Oct. 10, ADMA stock crashed more than 16% after the company's auditor unexpectedly resigned. That triggered a key sell signal, but shares have quickly recovered from those losses. In early November, ADMA completed a deal with KPMG, which signed on as its new independent registered public accounting firm.
Its latest quarterly results, reported on Nov. 8, showed adjusted earnings of 15 cents per share, above expectations for 13 cents. Earnings skyrocketed from a 1-cent gain in the year-earlier period. Sales also surged 78% to $119.8 million, beating forecasts for $105.8 million.
For the full year, Wall Street forecasts the company to earn 52 cents per share, with growth of 38% to 72 cents in 2025, per IBD MarketSurge.
This Industry Group — And 4 IPOs — Polish 20 'Perfect' Gems
On Nov. 8, ADMA stock broke out past a short cup base's 21.13 buy point, but shares quickly pulled back below the buy point. In recent sessions, they found much-needed support at the 50-day moving average line.
Now, ADMA stock is rebounding from that level and is back above the buy point. The 5% buy range goes up to 22.19.
Bullishly, the stock's relative strength line hit a new high in recent weeks. That confirms shares are beating the performance of the S&P 500.
Amid powerful gains in recent years, ADMA stock boasts a best-possible 99 Composite Rating from Investor's Business Daily, according to IBD Stock Checkup.
Cracks Emerge In Nvidia's AI Armor. What's An Investor To Do?
Three recent IBD 50 Growth Stocks To Watch picks are among the best stocks to buy and watch.
| Company | Symbol | Buy point | Type of base |
|---|---|---|---|
| Atour Lifestyle | (ATAT) | 29.15 | Consolidation |
| GeneDx | (NVDA) | 89.11 | Consolidation |
| Rhythm Pharmaceuticals | (RYTM) | 55.64 | Consolidation |
Follow Scott Lehtonen on X at @IBD_SLehtonen for more on the best stocks to buy and watch and the Dow Jones Industrial Average.
YOU MAY ALSO LIKE:
IBD's New Exposure Levels
Top Growth Stocks To Buy And Watch
Learn How To Time The Market With IBD's ETF Market Strategy
Find The Best Long-Term Investments With IBD Long-Term Leaders
Spot Buy Points And Sell Signals With MarketSurge Pattern Recognition
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。